Cantor Fitzgerald analyst Prakhar Agrawal downgraded Keros Therapeutics (KROS) to Neutral from Overweight.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Biotech Alert: Searches spiking for these stocks today
- Keros Therapeutics downgraded at Wedbush after removing PAH, obesity programs
- Keros Therapeutics downgraded to Neutral from Outperform at Wedbush
- Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler
- Keros Therapeutics price target lowered to $41 from $44 at Scotiabank